Skip to main content
SpringerLink
Log in

Healing Delayed But Generally Reliable After Bisphosphonate-associated Complete Femur Fractures Treated with IM Nails

  • Symposium: Femur Fractures: Contemporary Treatment Approaches
  • Published:
Clinical Orthopaedics and Related Research®

Abstract

Background

Bisphosphonate therapy for osteoporosis has been associated with atypical femoral fractures. To date, there have been few reports in the literature regarding the preoperative and postoperative courses of patients who have sustained bisphosphonate-associated complete atypical femur fractures.

Objectives/purposes

The purposes of this study were to (1) characterize the preoperative course of patients who eventually presented with bisphosphonate-associated complete atypical femur fractures (duration of bisphosphonate treatment, pain history, risk of converting a nondisplaced fracture to a complete fracture); (2) evaluate the percentage of patients who achieved radiographic union of those fractures after treatment; and (3) determine the patients’ recovery of function using the Short Musculoskeletal Functional Assessment.

Methods

Thirty-three patients with 41 atypical, low-energy femur fractures associated with ≥ 5 years of bisphosphonate use were treated with intramedullary nailing between 2004 and 2011 at one center. The main outcome measurements were Short Musculoskeletal Functional Assessment for function and radiographic evaluation for fracture healing. Patients had been treated with bisphosphonates for an average of 8.8 years (range, 5–20 years) before presentation.

Results

Patients reported a mean of 6 months of pain before presentation (range, 1–8 months). Sixty-six percent of patients with surgically treated complete fractures became pain-free and 98% were radiographically healed by 12 months. Sixty-four percent of patients who underwent intramedullary nailing reported a functional return to baseline within 1 year. Patients who reported major functional limitations at latest followup listed pain and apprehension as the major causes of their limitation.

Conclusions

Patients with surgically treated bisphosphonate-associated complete femur fractures achieved generally reliable although delayed fracture healing if malaligned, and nearly two-thirds of patients returned to self-reported baseline function within 1 year.

Level of Evidence

Level III, therapeutic study. See Guidelines for Authors for a complete description of levels of evidence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1A–C
Fig. 2
Fig. 3A–B

Similar content being viewed by others

References

  1. Audran M, Cortet B, Thomas T. What do we know about atypical femoral fractures? Insights and enigmas. Joint Bone Spine. 2011;78:568–571.

    Article  PubMed  Google Scholar 

  2. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535–1541.

    Article  CAS  PubMed  Google Scholar 

  3. Capeci CM, Tejwani NC. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg Am. 2009;91:2556–2561.

    Article  PubMed  Google Scholar 

  4. Chan SS, Rosenberg ZS, Chan K, Capeci C. Subtrochanteric femoral fractures in patients receiving long-term alendronate therapy: imaging features. AJR Am J Roentgenol. 2010;194:1581–1586.

    Article  PubMed  Google Scholar 

  5. Chrischilles EA, Dasbach EJ, Rubenstein LM, Cook JR, Tabor HK, Black DM. The effect of alendronate on fracture-related healthcare utilization and costs: the fracture intervention trial. Osteoporos Int. 2001;12:654–660.

    Article  CAS  PubMed  Google Scholar 

  6. Das De S, Setiobudi T, Shen L. A rational approach to management of alendronate-related subtrochanteric fractures. J Bone Joint Surg Br. 2010;92:679–686.

    Article  Google Scholar 

  7. Dell R, Greene D. Is osteoporosis diseases management cost effective? Curr Osteoporos Rep. 2010;8:49–55.

    Article  PubMed  Google Scholar 

  8. Egol KA, Park JH, Prensky C, Rosenberg ZS, Peck V, Tejwani NC. Surgical treatment improves clinical and functional outcomes for patients who sustain incomplete bisphosphonate-related femur fractures. J Orthop Trauma. 2014 Sep 14 [Epub ahead of print].

  9. Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, Lombardi A, Black DM. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res. 2004;19:1259–1269.

    Article  CAS  PubMed  Google Scholar 

  10. Girgis CM, Seibel MJ. Guilt by association? Examining the role of bisphosphonate therapy in the development of atypical femur fractures. Bone. 2011;48:963–965.

    Article  CAS  PubMed  Google Scholar 

  11. Giusti A, Hamdy NA, Papapoulos SE. Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone. 2010;47:169–180.

    Article  CAS  PubMed  Google Scholar 

  12. Hollick R, Reid D. Role of bisphosphonates in the management of postmenopausal osteoporosis: an update on recent safety anxieties. Menopause Int. 2011;17:66–72.

    Article  PubMed  Google Scholar 

  13. Hunsaker FG, Cioffi DA, Amadio PC, Wright JG, Caughlin B. The American Academy of Orthopaedic Surgeons outcomes instruments: normative values from the general population. J Bone Joint Surg Am. 2002;84:208–215.

    PubMed  Google Scholar 

  14. Ing-Lorenzini K, Desmeules J, Plachta O, Suva D, Dayer P, Peter R. Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. Drug Safety. 2009;32:775–785.

    Article  CAS  PubMed  Google Scholar 

  15. Johnell O, Kanis J. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17:1726–1733.

    Article  CAS  PubMed  Google Scholar 

  16. Kanis JA. Assessment of Osteoporosis at the Primary Health-Care Level, WHO Technical Report. Sheffield, UK:WHO Scientific Group,World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield; 2007.

  17. Koval KJ, Zuckerman JD, eds. Fractures in the Elderly. New York, NY, USA: Lippincott-Raven Publishers; 1998.

    Google Scholar 

  18. Lenart BA, Neviaser AS, Lyman S, Chang CC, Edobor-Osula F, Steele B, van der Meulen MC, Lorich DG, Lane JM. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int. 2009;20:1353–1362.

    Article  CAS  PubMed  Google Scholar 

  19. Li J, Mashiba T, Burr D. Bisphosphonate treatment suppresses not only stochnastic remodeling but also the targeted repair of microdamage. Calcif Tissue Int. 2001;69:281–286.

    Article  CAS  PubMed  Google Scholar 

  20. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res. 2000;15:613–620.

    Article  CAS  PubMed  Google Scholar 

  21. Mashiba T, Turner C, Hirano T, Forwood M, Johnston C, Burr D. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone. 2001;28:524–531.

    Article  CAS  PubMed  Google Scholar 

  22. Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 2008;22:346–350.

    Article  PubMed  Google Scholar 

  23. Nieves JW, Cosman F. Atypical subtrochanteric and femoral shaft fractures and possible association with bisphosphonates. Curr Osteoporos Rep. 2010;8:34–39.

    Article  PubMed  Google Scholar 

  24. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90:1294–1301.

    Article  CAS  PubMed  Google Scholar 

  25. Rosenberg ZS, La Rocca Vieira R, Chan SS, Babb J, Akyol Y, Rybak LD, Moore S, Bencardino JT, Peck V, Tejwani NC, Egol KA. Bisphosphonate-related complete atypical subtrochanteric femoral fractures: diagnostic utility of radiography. AJR Am J Roentgenol. 2011;197:954–960.

    Article  PubMed  Google Scholar 

  26. Sellmeyer DE. Atypical fractures as a potential complication of long-term bisphosphonate therapy. JAMA. 2010;304:1480–1484.

    Article  CAS  PubMed  Google Scholar 

  27. Somford MP, Draijer FW, Thomassen BJ, Chavassieux PM, Boivin G, Papapoulos SE. Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. J Bone Miner Res. 2009;24:1736–1740.

    Article  PubMed  Google Scholar 

  28. Wang K, Moaveni A, Dowrick A, Liew S. Alendronate-associated femoral insufficiency fractures and femoral stress reactions. J Orthop Surg (Hong Kong). 2011;19:89–92.

    Google Scholar 

  29. Watts N, Diab D. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab. 2010;95:1555–1565.

    Article  CAS  PubMed  Google Scholar 

  30. Weil YA, Rivkin G, Safran O, Liebergall M, Foldes AJ. The outcome of surgically treated femur fractures associated with long-term bisphosphonate use. J Trauma. 2011;71:186–190.

    Article  CAS  PubMed  Google Scholar 

  31. Yoon RS, Hwang JS, Beebe KS. Long-term bisphosphonate usage and subtrochanteric insufficiency fractures. J Bone Joint Surg Br. 2011;93:1289–1295.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank the NYU Langone Medical Center and the Jamaica Hospital Medical Center for providing the facilities and resources to perform clinical research and contribute to the medical community.

Author information

Authors and Affiliations

  1. Department of Orthopaedic Surgery, New York University Hospital for Joint Diseases, 301 E 17th Street, New York, NY, 10003, USA

    Kenneth A. Egol MD, Ji Hae Park BS & Nirmal C. Tejwani MD

  2. Jamaica Hospital Medical Center, Jamaica, New York, NY, USA

    Kenneth A. Egol MD

  3. Department of Radiology, NYU Langone Medical Center, New York, NY, USA

    Zehava Sadka Rosenberg MD

  4. Department of Medicine, NYU Langone Medical Center, New York, NY, USA

    Valerie Peck MD

Authors
  1. Kenneth A. Egol MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ji Hae Park BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zehava Sadka Rosenberg MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Valerie Peck MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nirmal C. Tejwani MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kenneth A. Egol MD.

Additional information

Each author certifies that he or she, or a member of his or her immediate family, has no funding or commercial associations (eg, consultancies, stock ownership, equity interest, patent/licensing arrangements, etc) that might pose a conflict of interest in connection with the submitted article.

All ICMJE Conflict of Interest Forms for authors and Clinical Orthopaedics and Related Research editors and board members are on file with the publication and can be viewed on request.

Clinical Orthopaedics and Related Research neither advocates nor endorses the use of any treatment, drug, or device. Readers are encouraged to always seek additional information, including FDA-approval status, of any drug or device prior to clinical use.

Each author certifies that his or her institution approved or waived approval for the reporting of this case and that all investigations were conducted in conformity with ethical principles of research.

About this article

Cite this article

Egol, K.A., Park, J.H., Rosenberg, Z.S. et al. Healing Delayed But Generally Reliable After Bisphosphonate-associated Complete Femur Fractures Treated with IM Nails. Clin Orthop Relat Res 472, 2728–2734 (2014). https://doi.org/10.1007/s11999-013-2963-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11999-013-2963-1

Keywords

Search

Navigation